Researchers have announced that the rVSV-ZEBOV vaccine has shown 100 % effectiveness in a Phase III large-scale trial of over 7000 people in Guinea. Read the full paper
With an emphasis on systems analyses, the VSV-EBOVAC project harnesses state-of-theart technologies that illuminate mechanisms behind the observed immunogenicity and reactogenicity of the rVSV-ZEBOV vaccine…
Professor Claire-Anne Siegrist from the University of Geneva in Switzerland, the principal investigator of the Geneva clinical trial, and Donata Medaglini the coordinator of the VSV-EBOVAC project,…
This three day event will be attended by over one hundred participants from the 42 ADITEC partner institutions which includes some of the most competitive…
Coordinated by the SVA, the VSV-EBOVAC project “Vaccine safety and immunogenicity signatures of human responses to rVSV-ZEBOV” brings together 12 leading international vaccine research institutes, both clinical and high tech, from 6…
The article focuses on the way that the EU shapes the course of research and ADITEC is highlighted on its success of comparing different companies’…
Vaccines have the potential to transformthe health of all individuals and to reduce the health inequality between rich and poor countries. However, to achieve these…